U.S. Study of Fibrocaps in Surgical Hemostasis

Not Applicable

Completed

Brief Summary: The purpose of this study was to characterize the safety and hemostatic activity of topical Fibrocaps in surgical patients when control of mild to moderate bleeding by standard surgical techniques was ineffective and/or impractical.

Detailed Description: This was a multi-center, prospective, randomized, single-blind, controlled, comparative efficacy and safety trial in 90 subjects undergoing spinal surgery, hepatic resection, specific soft tissue dissection, or peripheral vascular surgery, ((including peripheral artery bypass and arteriovenous graft formation for hemodialysis using either Polytetrafluoroethylene (PTFE) or native grafts)). Subjects were randomized in a 2:1 ratio to Fibrocaps + Gelfoam or Gelfoam on the day of surgery.

Use of the Fibrospray device was optional for spinal and vascular surgeries, but required for the general surgery procedures. All investigators using the Fibrospray device were trained on the correct and safe set-up and use of Fibrocaps and the Fibrospray device prior to participating in this clinical trial.

Recruitment & Eligibility

Inclusion Criteria

male or female 18 years of age or older
Subjects who are able and willing to provide written and signed informed consent
All subjects willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
A life expectancy of at least one year

Intra-Operative inclusion criteria

Presence of mild or moderate bleeding/oozing when control by conventional surgical techniques, including but not limited to suture, ligature and cautery is ineffective or impractical
Absence of intraoperative complications other than bleeding which, in the opinion of the investigator, may interfere with the assessment of efficacy or safety
No intraoperative use of a topical hemostat containing thrombin
Approximate Target Bleeding Site surface area of no more than 100 square centimeters

Exclusion Criteria

Pregnant or lactating women
Has a known intolerance to blood products or to Fibrocaps components
Unwilling to receive human blood products
Subject has a known allergy to porcine gelatin
Has a mental or physical condition that would, in the opinion of the investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol
Currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the start of this trial, or is planning participation in another clinical trial during the 4 weeks after surgery
Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the investigator
Aspartate Aminotransferase (AST) or Alanine aminotransferase (ALT) 3 times (or more) the upper limit normal range during screening, except for subjects undergoing liver resection surgery where there is no upper limit for these analytes due to the nature of their disease.
Platelets < 10 x 10^9 /L during screening
Activated partial thromboplastin time (aPTT) > 100 seconds during screening
International normalized ratio (INR)greater than 2.5 during screening

Arm && Interventions

Group	Intervention	Description
Gelfoam	Gelfoam	Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
Fibrocaps + Gelfoam	Fibrocaps (fibrin sealant)	After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.

Primary Outcome Measures

Name	Time	Method
Mean Time to Hemostasis (TTH)	0-10 minutes	Time to hemostasis recorded from the first application of study treatment until cessation of bleeding

Secondary Outcome Measures

Name	Time	Method
Number of Patients Achieving Hemostasis at 10 Minutes	10 minutes
Number of Subjects Achieving Hemostasis at 3 Minutes	3 minutes
Safety	28 Days	Number of participants with Adverse events and clinically-significant changes/findings on labs and physical examination as well as incidence of re-operation for bleeding at the TBS
Number of Participants Achieving Hemostasis at 5 Minutes	5 minutes